Back to results

Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics

Primary Purpose

Parkinson Disease

Status

Completed

Phase

Phase 1

Locations

Portugal

Study Type

Interventional

Intervention

Placebo oral capsule

Sinemet® 100/25

Comtan®

BIA 6-512 25 mg

BIA 6-512 100 mg

About this trial

This is an interventional treatment trial for Parkinson Disease

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Male or female subjects aged between 18 and 45 years, inclusive.
Subjects of body mass index (BMI) between 19 and 30 kg/m2, inclusive.
Subjects who were healthy as determined by pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead ECG.
Subjects who had clinical laboratory tests clinically acceptable at screening and admission.
Subjects who had negative tests for HBsAg, anti-HCVAb and anti-HIV-1 and anti-HIV-2 Ab at screening.
Subjects who had a negative screen for alcohol and drugs of abuse at screening and admission.
Subjects who were non-smokers or who smoked less than 10 cigarettes or equivalent per day.
Subjects who were able and willing to give written informed consent.
(If female) She was sterile or, if of childbearing potential, she used one of the following methods of contraception: double barrier, intrauterine device or abstinence.
(If female) She had a negative urine pregnancy test at screening and admission.

Exclusion Criteria:

Subjects who did not conform to the above inclusion criteria, OR
Subjects who had a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders.
Subjects who had a clinically relevant surgical history.
Subjects who had a clinically relevant family history.
Subjects who had a history of relevant atopy.
Subjects who had a history of relevant drug hypersensitivity.
Subjects who had a history of alcoholism or drug abuse.
Subjects who consumed more than 21 units of alcohol a week.
Subjects who had a significant infection or known inflammatory process on screening or admission.
Subjects who had acute gastrointestinal symptoms at the time of screening or admission (e.g., nausea, vomiting, diarrhoea, heartburn).
Subjects who had used prescription or over-the-counter medication within 2 weeks of admission.
Subjects who had used any investigational drug or participated in any clinical trial within 3 months prior to screening.
Subjects who had donated or received any blood or blood products within 3 months prior to screening.
Subjects who were vegetarians, vegans or have medical dietary restrictions.
Subjects who cannot communicate reliably with the investigator.
Subjects who were unlikely to co-operate with the requirements of the study.
(If female) She was pregnant or breast-feeding.
(If female) She was of childbearing potential and she did not use an approved effective contraceptive method or she used oral contraceptives.

Sites / Locations

Human Pharmacology Unit (UFH)

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Arm Label

Group 1 (BIA 6-512 25 mg + Placebo)

Group 2 (BIA 6-512 50 mg + Placebo)

Group 3 (BIA 6-512 100 mg + Placebo)

Group 4 (BIA 6-512 200 mg + Placebo)

Arm Description

Single-doses were prepared as follows: BIA 6-512 25 mg dose = 1 capsule of 25 mg plus 1 capsule of placebo In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions.

Single-doses were prepared as follows: BIA 6-512 50 mg dose = 2 capsules of 25 mg In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions.

Single-doses were prepared as follows: BIA 6-512 100 mg dose = 1 capsule of 100 mg plus 1 capsule of placebo In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions.

Single-doses were prepared as follows: BIA 6-512 200 mg dose = 2 capsules of 100 mg In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions.

Outcomes

Primary Outcome Measures

Maximum observed plasma drug concentration (Cmax) - Day 1

Pharmacokinetic parameters for BIA 6-512, levodopa, 3-O-methyldopa (3-OMD) on Day 1 - Day of administration of BIA 6-512/Placebo concomitantly with 1 tablet of levodopa/carbidopa 100/25 mg (Sinemet® 100/25)

Time at which the Cmax occurred (tmax) - Day 1

Area under the plasma concentration versus time curve (AUC) from time zero to the last sampling time at which concentrations were at or above the limit of quantification (AUC0-t) - Day 1

AUC from time zero to the infinity (AUC0-∞) - Day 1

Elimination rate constant (λz) - Day 1

Apparent elimination half-life (t1/2) - Day 1

Maximum observed plasma drug concentration (Cmax) - Day 2

Pharmacokinetic parameters for BIA 6-512, levodopa, 3-O-methyldopa (3-OMD) and entacapone on day 2 - Day of administration of BIA 6-512/Placebo concomitantly with 1 tablet of levodopa/carbidopa 100/25 mg (Sinemet® 100/25) plus 1 tablet of entacapone 200 mg (Comtan®). Administration occurred 24 h after the time of administration in Day 1.

Time at which the Cmax occurred (tmax) - Day 2

Area under the plasma concentration versus time curve (AUC) from time zero to the last sampling time at which concentrations were at or above the limit of quantification (AUC0-t) - Day 2

AUC from time zero to the infinity (AUC0-∞) - Day 2

Elimination rate constant (λz) - Day 2

Apparent elimination half-life (t1/2) - Day 2

Secondary Outcome Measures

Full Information

NCT ID

NCT03091868

First Posted

March 21, 2017

Last Updated

March 21, 2017

Sponsor

Bial - Portela C S.A.

1. Study Identification

Unique Protocol Identification Number

NCT03091868

Brief Title

Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics

Official Title

A Double-blind, Randomised, Placebo-controlled Study in Healthy Volunteers to Investigate the Tolerability and Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Carbidopa 100/25 mg or With a Single-dose of Levodopa/Carbidopa 100/25 mg Plus a Single-dose of Entacapone 200 mg

Study Type

Interventional

2. Study Status

Record Verification Date

March 2017

Overall Recruitment Status

Completed

Study Start Date

November 3, 2004 (Actual)

Primary Completion Date

February 28, 2005 (Actual)

Study Completion Date

February 28, 2005 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Bial - Portela C S.A.

4. Oversight

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

5. Study Description

Brief Summary

To investigate the effect of rising oral single-doses of BIA 6-512 (25 mg, 50 mg, 100 mg and 200 mg) on levodopa pharmacokinetics when administered in combination with a single-dose of immediate release levodopa/carbidopa 100/25 mg (Sinemet® 100/25) or with a single-dose of Sinemet® 100/25 plus a single-dose of entacapone (Comtan®) 200 mg and to assess the tolerability and safety of rising single oral doses of BIA 6-512 when administered in combination with a single-dose of Sinemet® 100/25 or with a single-dose of Sinemet® 100/25 plus a single-dose of Comtan® 200 mg.

Detailed Description

Single centre, double-blind, randomised, placebo-controlled study in four sequential groups of healthy subjects. Eligible subjects were admitted to the UFH on the day prior to receiving the first study medication. On the morning of the first dosing day (Day 1), subjects received BIA 6-512/Placebo concomitantly with Sinemet® 100/25; on the morning of the second dosing day (Day 2), subjects received BIA 6-512/Placebo concomitantly with Sinemet® 100/25 and Comtan® 200 mg. Products were administered in fasting conditions (at least 8 hours). Subjects remained confined in the UFH from admission (Day 0) until at least 24 h post last dose (Day 3); then, they were discharged and will return for the follow-up visit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Parkinson Disease

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 1

Interventional Study Model

Sequential Assignment

Masking

ParticipantInvestigator

Allocation

Randomized

Enrollment

80 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Group 1 (BIA 6-512 25 mg + Placebo)

Arm Type

Experimental

Arm Description

Arm Title

Group 2 (BIA 6-512 50 mg + Placebo)

Arm Type

Experimental

Arm Description

Arm Title

Group 3 (BIA 6-512 100 mg + Placebo)

Arm Type

Experimental

Arm Description

Arm Title

Group 4 (BIA 6-512 200 mg + Placebo)

Arm Type

Experimental

Arm Description

Intervention Type

Drug

Intervention Name(s)

Placebo oral capsule

Intervention Description

Matching placebo capsules. Oral administration.

Intervention Type

Drug

Intervention Name(s)

Sinemet® 100/25

Intervention Description

Single-dose of immediate release levodopa/carbidopa 100/25 mg consisted of 1 tablet of Sinemet® 100/25. Route of administration: Oral.

Intervention Type

Drug

Intervention Name(s)

Comtan®

Intervention Description

Single-dose of entacapone 200 mg consisted of 1 tablet of Comtan®. Route of administration: Oral.

Intervention Type

Drug

Intervention Name(s)

BIA 6-512 25 mg

Intervention Description

BIA 6-512 capsules strengths 25 mg. Oral administration.

Intervention Type

Drug

Intervention Name(s)

BIA 6-512 100 mg

Intervention Description

BIA 6-512 capsules strengths 100 mg. Oral administration.

Primary Outcome Measure Information:

Title

Maximum observed plasma drug concentration (Cmax) - Day 1

Description

Time Frame

pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose

Title

Time at which the Cmax occurred (tmax) - Day 1

Description

Time Frame

pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose

Title

Area under the plasma concentration versus time curve (AUC) from time zero to the last sampling time at which concentrations were at or above the limit of quantification (AUC0-t) - Day 1

Description

Time Frame

pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose

Title

AUC from time zero to the infinity (AUC0-∞) - Day 1

Description

Time Frame

pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose

Title

Elimination rate constant (λz) - Day 1

Description

Time Frame

pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose

Title

Apparent elimination half-life (t1/2) - Day 1

Description

Time Frame

pre-dose, ¼, ½, ¾, 1, 1½, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose

Title

Maximum observed plasma drug concentration (Cmax) - Day 2

Description

Time Frame